Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-21-033284
Filing Date
2021-10-01
Accepted
2021-10-01 16:31:39
Documents
12
Period of Report
2021-07-16
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A brhc10029466_8ka.htm   iXBRL 8-K/A 29001
  Complete submission text file 0001140361-21-033284.txt   169295

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA btx-20210716.xsd EX-101.SCH 3929
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20210716_lab.xml EX-101.LAB 23242
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20210716_pre.xml EX-101.PRE 16535
5 EXTRACTED XBRL INSTANCE DOCUMENT brhc10029466_8ka_htm.xml XML 4410
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-11460 | Film No.: 211299350
SIC: 2834 Pharmaceutical Preparations